Brief: Tiziana Announces Reduction Of Side Effects Commonly Seen With Discontinuation Of GLP-1 Agonists With Nasal Anti-CD3
10/01/2025 13:15
Jan 10 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA ANNOUNCES REDUCTION OF SIDE EFFECTS COMMONLY SEEN
WITH
DISCONTINUATION OF GLP-1 AGONISTS WITH NASAL ANTI-CD3
* TIZIANA LIFE SCIENCES LTD - GLP-1 DRUGS FACE LONG TERM
TOLERABILITY ISSUES
* TIZIANA LIFE SCIENCES LTD - FDA ALLOWS ADDITIONAL 20
PATIENTS IN
FORALUMAB EXPANDED ACCESS PROGRAM
Source text: urn:newsml:reuters.com:*:nGNX1JJ8Xz
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsBrief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Tiziana Life Sciences rises as nasal MS drug shows promise in early study